Shijiazhuang Yiling Pharmaceutical Co., Ltd. Stock

Equities

002603

CNE1000015S0

Pharmaceuticals

End-of-day quote Shenzhen S.E. 18:00:00 2024-06-17 EDT 5-day change 1st Jan Change
16.81 CNY 0.00% Intraday chart for Shijiazhuang Yiling Pharmaceutical Co., Ltd. -5.46% -27.13%

Financials

Sales 2024 * 11.15B 1.54B 2.11B Sales 2025 * 13.68B 1.89B 2.59B Capitalization 28.08B 3.87B 5.31B
Net income 2024 * 1.53B 211M 290M Net income 2025 * 2.26B 311M 427M EV / Sales 2024 * 2.41 x
Net cash position 2024 * 1.18B 162M 223M Net cash position 2025 * 2.35B 324M 445M EV / Sales 2025 * 1.88 x
P/E ratio 2024 *
18.3 x
P/E ratio 2025 *
12.4 x
Employees 13,958
Yield 2024 *
1.39%
Yield 2025 *
2.15%
Free-Float 41.69%
More Fundamentals * Assessed data
Dynamic Chart
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Approves Cash Dividend Per 10 Shares for 2023 CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Yiling Pharmaceutical Gets Nod for China Clinical Trial of Tracheobronchitis Drug MT
Yiling Pharmaceutical's Lianhua Qingke Tablets Gets Nod to Become Over-the-Counter Drug; Shares Up 4% MT
Yiling Pharmaceutical Gets Nod to Trial Huoxia Cold Granules MT
Yiling Pharmaceutical Presents Clinical Data on Cardiovascular Drug at Beijing Conference MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Yiling Pharmaceutical Gets Green Light to Trial Acute Myeloid Leukemia Drug MT
Yiling Pharmaceutical Gets Greenlight to Trial G201-Na Capsules MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Announces Implementation of Cash Dividend for 2022, Payable on 17 July 2023 CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Approves Cash Dividend for 2022 CI
Yiling Pharma's Hypertension Drug Passes Regulatory Evaluation in China MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2022 CI
More news
1 week-5.46%
Current month-7.43%
1 month-13.40%
3 months-22.75%
6 months-29.67%
Current year-27.13%
More quotes
1 week
16.68
Extreme 16.68
17.80
1 month
16.68
Extreme 16.68
19.50
Current year
16.68
Extreme 16.68
24.47
1 year
16.68
Extreme 16.68
27.25
3 years
15.38
Extreme 15.38
53.96
5 years
7.15
Extreme 7.15
53.96
10 years
7.08
Extreme 7.0786
53.96
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 04-12-31
Director of Finance/CFO 51 96-12-31
Director/Board Member 54 15-03-15
Members of the board TitleAgeSince
Founder 75 01-08-27
Chief Executive Officer 49 04-12-31
Director of Finance/CFO 51 96-12-31
More insiders
Date Price Change Volume
24-06-18 16.81 0.00% 8,228,174
24-06-17 16.81 -1.23% 12,280,700
24-06-14 17.02 -1.28% 12,149,840
24-06-13 17.24 -3.20% 15,741,430
24-06-12 17.81 +0.17% 7,413,986

End-of-day quote Shenzhen S.E., June 17, 2024

More quotes
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company mainly provides cardiovascular and cerebrovascular drugs and anti-cold drugs. The Company also provides food and beverage products. The Company distributes its products within domestic market and to overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
16.81 CNY
Average target price
20.93 CNY
Spread / Average Target
+24.53%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 002603 Stock